Albumin is a serum protein that is synthesized in the liver and plays a role in determining oncotic pressure. Serum albumin levels can be reduced under conditions of poor nutrition, advanced liver disease, and catabolic conditions associated with cancer or inflammatory diseases. Decreased plasma albumin levels correlate with an increased risk of patient morbidity and mortality. Albumin transfusion becomes one of the therapeutic treatments to overcome hypoalbuminemia. Research on the effectiveness of albumin has not been done much. In this regard, this study aims to determine the effectiveness of albumin studies on increasing albumin levels in patients and the difference in effectiveness of albumin administration in a variety of different patient conditions. This research is a retrospective observational study with a cross sectional research design and the sampling technique used was purposive sampling method. The study was conducted at PKU Muhammadiyah Hospital in Yogyakarta City by collecting data on albumin use in various patient conditions through laboratory data from patient medical records in the January-December 2017 period with a total sample of 80 patients who met the inclusion and exclusion criteria. Analysis of albumin effectiveness can be seen from the increase in albumin levels using the Wilcoxon statistical test method while the analysis of albumin effectiveness in patient conditions using paired sample t test. The results showed that administration of albumin was most commonly prescribed in patients with diabetes mellitus (19%) followed by anorexia patients (6%), sepsis patients (5%) and Heart Failure patients (5%). There were differences in levels before and after administration of albumin therapy as indicated by a statistically significant increase in albumin value after administration of albumin therapy (P = 0,000). Differences between patients' conditions indicate that administration of albumin effectively increases albumin levels significantly in patients with diabetes mellitus, anorexia and lung tumors (p <0.05), but not significantly in patients with sepsis, stroke, chronic diarrhea, pneumonia, and heart failure (P > 0.05).